A new British Journal of Pharmacology review examines how phosphodiesterase-5 (PDE5) inhibitors, which were originally approved to treat erectile dysfunction, are finding clinical uses for a wide variety of conditions.
PDE5 inhibitors cause blood vessel dilation by targeting a particular cellular pathway that is involved in many normal physiological functions and in the pathophysiology of a wide range of diseases.
PDE5 inhibitors likely have effects on many organs and functions, and they have been approved to treat lower urinary tract symptoms and pulmonary arterial hypertension. They are also being used off-label to treat conditions including diabetes and cancer.
The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. It publishes high quality original research and authoritative reviews. Each year a range of themed issues are published and a must-read supplement, the Concise Guide to Pharmacology, is published biennially.
The journal is now published in an online-only format. Issues are published fortnightly but are no longer printed; however, authors are still able to order offprints of their own articles through Author Services.